Puma Biotechnology (NASDAQ:PBYI) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate of $(0.13) by 69.23 percent. This is a 140 percent decrease over earnings of $0.10 per share from the same period last year. The company reported quarterly sales of $44.800 million which beat the analyst consensus estimate of $42.000 million by 6.67 percent. This is a 2.61 percent decrease over sales of $46.000 million the same period last year.